

Leukocare appoints Dr. Georg Dönges as Chief Financial Officer

Martinsried/Munich, Germany, May 27, 2021

Leukocare AG, a biotechnology company specialized in the field of biopharmaceutical formulation development, has appointed Dr. Georg Dönges as Chief Financial Officer. Georg has led the company's financial department as Vice President Finance for the last three years. Before joining Leukocare, Georg had spent more than ten years in leading positions in biotech and other industries. Being a molecular biologist by training, he has achieved an impressive career path in various roles and functions in financial departments of public companies, e.g. as Head of Investor Relations at MediGene AG, Martinsried, Germany, and as Manager Finance Transformation coordinating the re-organization of corporate finance at GfK SE, Nuremberg, Germany, a KKR portfolio company. Georg earned a PhD at the Max-Planck-Institute of Biochemistry, Martinsried, Germany, and is a Certified International Investment Analyst (CIIA). Georg joined Leukocare in January 2018 and built the company's finance department including the insourcing of accounting and controlling functions. He oversaw two financing rounds as well as the founding of the company's US-subsiidiary Leukocare Inc., for which he acts as CFO and co-managing director.

Michael Scholl, Chief Executive Officer, said, "I am very pleased to announce Georg's appointment as Leukocare's new CFO. We have been working together for a number of years and successfully closed several deals that laid the foundation for the company's growth. Leukocare's ambitious future corporate goals require strategic and solid financial management and I am convinced that Georg is the perfect choice for this role. He brings a deep understanding and many years of relevant experience from both aspects – biotech and finance – to the table. I'm very much looking forward to further collaborating with him."

Dr. Georg Dönges, Chief Financial Officer, commented, "Over the last few years, I've been closely involved in the company's growth and took part in the ongoing development of its corporate strategy. I am proud to take up the role as CFO of this exciting company and to support Leukocare in further enhancing its unique technology as well as expanding its business."

About Leukocare AG

Leukocare AG, located in Martinsried/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence.

The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product's needs.

Leukocare's superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.

www.leukocare.com

Contact:

Michael Scholl

CEO

michael.scholl@leukocare.com

+49 (0) 89 7801 6650

Rebekka Ströver

Specialist Communications & Marketing

rebekka.stroeever@leukocare.com

+ 49 (0) 89 7801 665 14